Nanoparticles coated with a DC-SIGN ligand (gp120), encapsulating tumor antigens (gp100) and combined with adjuvants (R848, polyI:C), are less uptaken by human moDCs and induce weaker CD4 T-cell responses compared to nanoparticles coated with anti-DC-SIGN antibodies (even if the action of cytotoxic T-cells is equivalent between the two strategies). The gene discussed is CD4; the disease is neoplasm.